10 serious COVID patients given Israeli drug leave hospital in one day –

0
256
10 serious COVID patients given Israeli drug leave hospital in one day – fr



An Israeli biotech company has found a 100% success rate in the first 10 patients treated with its drug in an early clinical trial at the Rambam Health Care Campus in Haifa.

The company, Bonus BioGroup, presented the preliminary results of its Phase I / II trial to its peers at the International Society for Cell & Gene Therapy conference and shared the results in a statement released to the Tel Stock Exchange. Aviv.

Jerusalem post reviewed the PowerPoint presented at the conference and the five-page letter sent to the exchange. The CEO and director of the company, Dr Shai Meretzki, told the Poster that the team is now working on publishing its findings in a peer-reviewed journal.

Bonus MesenCure, which consists of activated mesenchymal stromal cells (MSCs) isolated from fatty tissue of healthy donors, has been shown to reduce inflammation, promote regeneration of diseased lung tissue, and relieve respiratory and other symptoms in patients with of life -threatening respiratory distress caused by COVID-19.

“So far, the results of treatment with the drug MesenCure are extremely impressive and an improvement over the results of other treatments,” said Dr Shadi Hamoud, principal investigator of the clinical trial and deputy director of the department of internal medicine E in Rambam.

He said the results were so promising that the hospital was already examining the use of the treatment for other indications.

Bonus reported from 10 COVID-19 patients aged 45 to 75, all with severe symptoms. Ninety percent of them also had co-morbidities.

The data showed a 40% decrease in lung inflammation due to treatment -om 55% to 15%, as seen on chest x-rays.

Additionally, patients showed significantly improved respiratory function, with blood oxygen saturation showing a 95% increase and lung function returning to almost completely normal levels after just one month.

Meretzki shared a lab image of a healthy lung, a diseased lung, and a lung treated with MesenCure.

“The treated lung looks almost identical to the normal, healthy lung – complete healing, complete prevention of lung damage,” Meretzki said.

More strikingly, patients were discharged from the hospital after a median of just one day after the injection.

And there have been no side effects associated with MesenCure, the company reported.

Meretzki said the trial followed patients for 30 days after treatment was given. All but one had survived. The deceased patient did not die from COVID-19 but from comorbidity.

Many patients with COVID-19 die from increased production of inflammatory molecules called cytokines, rather than the virus itself, Meretzki explained. When the immune system secretes too many cytokines, a “cytokine storm” can break out. Such an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress syndrome or failure, and eventually death.

Bonus was founded in 2008. It has worked with MSC for a decade from its headquarters in Haifa, where it developed its flagship product, a tissue engineered bone graft that is also based on MSC.

Meretzki said that MSCs are cells “that are found in all of us; they are responsible for damage control and a variety of daily activities.

When the coronavirus outbreak began in early 2020, Bonus began investigating the potential of MSCs to possibly reduce the cytokine storm in COVID-19 patients.

The phase II trial is expected to continue in Rambam and include 50 additional patients. However, due to the low level of infection in Israel, Bonus also applied for permission to conduct the trial in Europe, Meretzki said.

He told the Poster that the phase II trial should be completed quickly once the remaining patients are fully enrolled.

There are still a high number of severe cases of COVID around the world. As of May 28, Meretzki said, there were 93,956 severe cases out of 14,603,155 total cases, or about 0.6%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here